Yi-Ling Chen Selected Research

Yi-Ling Chen Research Topics

Disease

34	Neoplasms (Cancer) 01/2022 - 08/2003
31	Inflammation (Inflammations) 01/2022 - 01/2011
16	Ischemia 04/2022 - 11/2012
13	Fibrosis (Cirrhosis) 01/2022 - 01/2014
10	Reperfusion Injury 01/2020 - 09/2015
9	Hypoxia (Hypoxemia) 01/2020 - 11/2012
8	Sepsis (Septicemia) 10/2017 - 04/2008
7	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2015
7	Shock 04/2019 - 01/2014
6	Infections 07/2021 - 10/2008
6	COVID-19 07/2021 - 06/2020
6	Carcinogenesis 01/2021 - 01/2015
6	Stomach Neoplasms (Stomach Cancer) 01/2021 - 10/2011
6	Body Weight (Weight, Body) 01/2020 - 07/2006
5	Infarction (Infarctions) 04/2022 - 08/2015
5	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 10/2011
5	Adenocarcinoma 01/2020 - 01/2015
5	Carcinoma (Carcinomatosis) 04/2015 - 10/2008
4	Heart Failure 04/2022 - 12/2015
4	Chronic Renal Insufficiency 04/2022 - 01/2015
4	Cardio-Renal Syndrome 04/2022 - 11/2016
4	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2016
4	Insulin Resistance 06/2018 - 02/2010
4	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2018 - 04/2008
3	Brain Infarction 07/2021 - 11/2016
3	Pain (Aches) 01/2020 - 09/2014
3	Ischemic Stroke 10/2019 - 02/2016
3	Brain Edema (Cerebral Edema) 01/2019 - 02/2016
3	Lung Injury 01/2018 - 11/2016
3	Bronchopulmonary Dysplasia 04/2008 - 07/2007
2	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 06/2018
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 10/2016
2	Multifocal Choroiditis 07/2021 - 01/2020
2	White Dot Syndromes 07/2021 - 01/2020
2	Stroke (Strokes) 07/2021 - 10/2008
2	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2021 - 12/2016
2	Human Influenza (Influenza) 01/2021 - 01/2010
2	Choroidal Neovascularization 01/2021 - 01/2020
2	Chronic Limb-Threatening Ischemia 10/2020 - 09/2018
2	Birth Weight (Birth Weights) 01/2020 - 08/2012
2	Hypertension (High Blood Pressure) 01/2020 - 01/2016

Drug/Important Bio-Agent (IBA)

42	Proteins (Proteins, Gene)FDA Link 04/2022 - 04/2011
21	Biomarkers (Surrogate Marker)IBA 04/2022 - 10/2011
21	Caspase 3 (Caspase-3)IBA 10/2020 - 11/2012
14	MelatoninIBA 01/2020 - 09/2015
11	salicylhydroxamic acid (SHAM)IBA 09/2018 - 08/2015
10	Cytochromes c (Cytochrome c)IBA 07/2021 - 09/2015
9	Therapeutic UsesIBA 01/2021 - 08/2004
9	Small Interfering RNA (siRNA)IBA 12/2017 - 01/2009
8	CreatinineIBA 04/2022 - 06/2010
8	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 08/2004
8	Messenger RNA (mRNA)IBA 01/2022 - 01/2014
8	Oxygen (Dioxygen)IBA 07/2021 - 08/2009
7	CollagenIBA 01/2019 - 01/2014
7	Matrix Metalloproteinases (MMPs)IBA 01/2019 - 09/2015
6	Exenatide (Byetta)FDA Link 01/2017 - 11/2015
5	CytokinesIBA 07/2021 - 08/2004
5	LipopolysaccharidesIBA 09/2018 - 01/2011
4	Interleukin-6 (Interleukin 6)IBA 07/2021 - 01/2014
4	Pharmaceutical PreparationsIBA 01/2020 - 01/2013
4	EnzymesIBA 01/2020 - 06/2010
4	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2019 - 12/2015
4	AntioxidantsIBA 01/2019 - 02/2014
4	Chemokine CCL5IBA 01/2017 - 01/2014
3	AntigensIBA 01/2022 - 12/2017
3	LipidsIBA 01/2022 - 10/2016
3	Peptides (Polypeptides)IBA 11/2020 - 04/2011
3	Complementary DNA (cDNA)IBA 01/2020 - 01/2015
3	Biological ProductsIBA 01/2020 - 06/2011
3	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2020 - 11/2016
3	Vitamin K 3 (Menadione)FDA Link 09/2018 - 01/2015
3	Triglycerides (Triacylglycerol)IBA 06/2018 - 02/2010
3	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 01/2018 - 02/2010
3	DNA VaccinesIBA 12/2017 - 08/2004
3	Indicators and Reagents (Reagents)IBA 01/2017 - 11/2015
3	InterleukinsIBA 11/2016 - 12/2014
3	Phosphotransferases (Kinase)IBA 06/2016 - 11/2012
3	LeptinIBA 01/2015 - 02/2010
2	Brain Natriuretic Peptide (Natrecor)FDA Link 04/2022 - 12/2015
2	NitrogenIBA 04/2022 - 01/2018
2	sacubitril and valsartan sodium hydrate drug combinationIBA 04/2022 - 08/2019
2	NPHS2 proteinIBA 01/2022 - 01/2018
2	Estrogen ReceptorsIBA 01/2022 - 01/2020
2	Cyclin D1IBA 01/2022 - 10/2017
2	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2021 - 08/2003
2	TransferasesIBA 03/2021 - 07/2010
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2021
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2021 - 01/2010
2	Histone Deacetylase InhibitorsIBA 01/2021 - 10/2011
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2021 - 01/2020
2	VaccinesIBA 06/2020 - 08/2004
2	ImmunosorbentsIBA 01/2020 - 06/2010
2	Beclin-1IBA 01/2020 - 08/2019

Therapy/Procedure

32	Therapeutics 04/2022 - 01/2009
4	Nephrectomy 01/2022 - 01/2015
4	Length of Stay 07/2021 - 04/2008
4	Ligation 01/2019 - 08/2015
4	Extracorporeal Shockwave Therapy 01/2019 - 01/2014
2	Aftercare (After-Treatment) 02/2021 - 09/2014
2	Transplantation 01/2020 - 02/2013